SoCalGal
11-01-2015, 10:29 PM
A friend just mentioned this clinical trial, MM302 by Merrimack, similar to TDM1 but with an anthracycline. Just thinking that it may wind up with less side effects than TDM1. That said, to qualify you still have to have TDM1 first and no history of anthracycline. Nice to know there is something else promising in the pipeline, and already phase2 clinical trial. Okay, not the most articulate post by me, but the whole time change, I'm not sure if I'm coming or going...
Here's some cut & paste:
MM-302 is a novel antibody-drug conjugated liposomal doxorubicin that specifically targets cancer cells overexpressing the HER2 receptor. As a liposomal encapsulation of doxorubicin, MM-302 is designed to allow for the selective uptake of drug into tumor cells while limiting exposure to healthy tissues, such as those of the heart.
Unlike other HER2-targeted agents, MM-302 is not designed to inhibit HER2 signaling pathways and relies on HER2 as a means to identify and gain access to the cancer cells. Once inside the cancer cell, the liposome breaks down and releases doxorubicin inside the cell, promoting cell death.
MM-302 is being evaluated in the phase 2 HERMIONE study in patients with advanced metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab in any setting and who have either progressed or are intolerant to both pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting. Patients must not have been previously treated with an anthracycline in any setting.
MM-302 is also being investigated in an ongoing phase 1 study.
Here's some cut & paste:
MM-302 is a novel antibody-drug conjugated liposomal doxorubicin that specifically targets cancer cells overexpressing the HER2 receptor. As a liposomal encapsulation of doxorubicin, MM-302 is designed to allow for the selective uptake of drug into tumor cells while limiting exposure to healthy tissues, such as those of the heart.
Unlike other HER2-targeted agents, MM-302 is not designed to inhibit HER2 signaling pathways and relies on HER2 as a means to identify and gain access to the cancer cells. Once inside the cancer cell, the liposome breaks down and releases doxorubicin inside the cell, promoting cell death.
MM-302 is being evaluated in the phase 2 HERMIONE study in patients with advanced metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab in any setting and who have either progressed or are intolerant to both pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting. Patients must not have been previously treated with an anthracycline in any setting.
MM-302 is also being investigated in an ongoing phase 1 study.